Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990–1996  by Cotter, Dennis J. et al.
Secular trends in recombinant erythropoietin therapy among the
U.S. hemodialysis population: 1990–1996
DENNIS J. COTTER, MAE THAMER, PAUL L. KIMMEL, and JOHN H. SADLER
Medical Technology and Practice Patterns Institute, Bethesda, Maryland; Department of Medicine, George Washington University
Medical Center, Washington, D.C.; and Independent Dialysis Foundation, Baltimore, Maryland, USA
Secular trends in recombinant erythropoietin therapy among the
U.S. hemodialysis population: 1990–1996.
Background. Chronic anemia is a major cause of morbidity
among the end-stage renal disease (ESRD) population. Recom-
binant erythropoietin (rHuEPO) has been recognized as a major
advance in the treatment of anemia among the ESRD population.
This study examines the secular trends in the use of and response
to rHuEPO therapy among severely, moderately and mildly
anemic hemodialysis patients.
Methods. We designed a cohort analytic study using seven years
of claims data. The study population comprised all facility-based
adult hemodialysis patients receiving rHuEPO therapy, who were
initially reimbursed by Medicare in each of the first quarter of the
calendar years 1990 through 1996 (N 5 64,957).
Results. Between 1990 and 1996, the mean rHuEPO dose
increased by 139% for the patient cohorts with a first observed
hematocrit ,0.25, 122% for the 0.25 to 0.29 cohorts, and 107%
for the $0.30 cohorts, and produced a 0.02 to 0.03 increase in
achieved hematocrit (A-Hct) over this time. Dosing of rHuEPO
did not appear to be influenced by patient or provider character-
istics, although African-Americans, the elderly, non-diabetics and
persons receiving dialysis in a non-profit facility had a larger
percent change in hematocrit compared to their counterparts
(P , 0.001).
Conclusions. The results of the clinical use of rHuEPO seven
years after FDA approval found in the general ESRD hemodial-
ysis population have not equaled the results obtained in the initial
clinical trials. Overall, our findings suggest that substantial in-
creases in rHuEPO dose provided to anemic patients have
resulted in only modest increases in hematocrit in the seven years
since rHuEPO’s introduction. Resistance to rHuEPO, prior
rHuEPO treatment, inadequate use of supplemental iron, and
policy and financial incentives may explain this finding.
Chronic anemia is a major cause of morbidity among the
end-stage renal disease (ESRD) patient population, partic-
ularly among those who undergo hemodialysis therapy, a
treatment that is provided to the vast majority of ESRD
patients. Anemia primarily results from a relative or abso-
lute deficiency of erythropoietin production by the kidneys.
Based on clinical trial results, recombinant human erythro-
poietin (rHuEPO) was recognized as being beneficial for
persons with anemia related to chronic renal failure and
end-stage renal disease (ESRD) [1, 2]. In Phase I and II
clinical trials, Eschbach et al reported that 25 patients had
a baseline hematocrit (Hct) of 0.194 6 0.027 and 12 of 25
patients were transfusion-dependent (receiving one or
more transfusion per month) when rHuEPO therapy began
[2]. Results of the combined Phase I and II clinical trial
indicated that among the study population of hemodialysis
patients with Hct of less than or equal to 0.25, a dose of 50
units per kilogram of body wt or higher thrice weekly
resulted in a dose-dependent increase in Hct. In some
cases, the average Hct doubled within four to five weeks
during the clinical trials.
In the subsequent Phase III multicenter clinical trial that
was designed to determine the overall effectiveness and
safety of rHuEPO in a larger population of ESRD patients,
rHuEPO was found to be effective for virtually all anemic
patients (Hct ,0.30) treated with hemodialysis [1]. Within
12 weeks, the baseline average Hct of 0.223 6 0.002
increased to 0.35 6 0.03 for 97% of all study patients using
an average dose of 300 or 150 U/kg body wt. Eschbach et al
also reported that as a group, the 333 Phase III patients
received an average of 0.52 units of blood per patient per
month before rHuEPO therapy. Patients became virtually
transfusion-independent after rHuEPO therapy began dur-
ing the clinical trial. More recently, the United States Renal
Data System (USRDS) also reported that outpatient use of
blood transfusions among the hemodialysis patients fell
from a level of 15% prior to introduction of rHuEPO
therapy to 5% by the last quarter of 1992 [3].
Medicare, which covers approximately 93% of all ESRD
patients in the United States, began coverage for rHuEPO
in June 1989. Medicare’s coverage and reimbursement
policy objectives were designed to encourage cost effective
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rHuEPO therapy. For patients to qualify for Medicare
coverage of rHuEPO therapy, the Health Care Financing
Administration (HCFA) requires a patient’s first observed
Hct to be below 0.30. Once rHuEPO therapy has been
initiated, the HCFA reimbursement policy established a
target Hct range of between 0.30 and 0.33, despite the fact
that the clinical trials used a much higher hematocrit target
of 0.32 to 0.38, with an average achieved hematocrit of 0.36.
Because of the narrowness of the target range selected by
HCFA, its contractors allow the Hct to rise to 0.36 before
initiating a medical review of rHuEPO claims. By imple-
menting this rule, the HCFA, for the first time, required the
reporting of a physiological parameter in its claims data.
This decision facilitated clinical research on the census of
ESRD patients regarding the effect of EPO dosing. In
January 1991, Congress changed the Medicare reimburse-
ment policy from a fixed “per administration” payment rate
independent of the amount administered to a variable
“total amount delivered” payment rate dependent on the
amount administered. The rationale for this change was
that “per administration” policy failed to encourage opti-
mal rHuEPO therapy (or encouraged ineffective low
rHuEPO doses), which resulted in many patients not
achieving the desired target Hct range of between 0.30 and
0.33.
The diffusion of rHuEPO among the ESRD population
was rapid, growing from 3.9% of ESRD beneficiaries in
July 1989 to 53.0% in only eleven months [4, 5]. Studies of
rHuEPO practice patterns in the early years of its availabil-
ity describe a low dosing regimen with concomitant low
achieved Hct, relative to clinical trial results [4, 6, 7]. In
subsequent years, after Congress changed HCFA’s reim-
bursement policy from a fixed rate to a variable rate, a
dramatic increase in the amount of rHuEPO administered
relative to the original first year dosing recommendations
occurred [8]. Financial reasons as well as target Hct levels
imposed by HCFA have been implicated in the increased
dosing of rHuEPO [9, 10]. Expenditures for rHuEPO are
substantial; in 1996, $1.2 billion was spent by Medicare for
rHuEPO therapy among the ESRD dialysis population
[11].
This study examines changes in rHuEPO dosing from
1990 to 1996 and the resultant impact on the Hct level,
adjusting for the changing patient case-mix during this
period. Unlike other published research, this study also
investigates whether moderately and mildly anemic
patients—who comprise an increasingly large majority of
the Medicare-reimbursed ESRD population—respond to
rHuEPO therapy in the same way as the severely anemic
patients studied in the clinical trials.
METHODS
Data source
Data for the study were obtained from HCFA’s ESRD
Program Management and Medical Information System
(PMMIS) database, HCFA’s Quarterly EPO Billing File,
and the annual ESRD Facility Survey. HCFA data are
obtained from dialysis providers and include information
on patient demographics, modality of dialysis, dates of
dialysis treatments, dates of kidney transplantation, date of
death, and the identity of dialysis providers. Information
related to patients whose claims are new to the PMMIS
(that is, the first time Medicare pays for rHuEPO services
for a particular beneficiary) during the first quarter for each
of the years 1990 through 1996, and all claims for the
succeeding four months were extracted from these data-
bases. Claims data represent the record of services deliv-
ered that is a necessary requirement for the payment of
services. All patients in the study were at least 18 years old
and received both rHuEPO and hemodialysis therapy on an
outpatient basis at a dialysis facility during the four-month
observation period.
Variables
The three key variables in this study are the following: (1)
mean rHuEPO dose per day (EPO Dose), defined as the
total dose of rHuEPO administered to a patient over the
study period divided by the outpatient days-of-risk based on
days-of-service reported in the claims; (2) the first observed
incident Hct (I-Hct), defined as the Hct reading taken prior
to the last administration of rHuEPO for the first billing
period in which Medicare paid for rHuEPO therapy; and
(3) achieved Hct (A-Hct), defined as the Hct reading taken
prior to the last administration of rHuEPO on the last bill
occurring in the patient’s final month of the observed
period. A mean rHuEPO dose for each study month was
used because individual observations for each rHuEPO
therapy session are not available using claims data. Addi-
tional variables of interest examined as predictors or con-
founders of EPO Dose, I-Hct, A-Hct, and the relationship
between these variables are: age, race, sex, provider type
(for-profit, not-for-profit, or government), number of dial-
ysis sessions, and the primary disease causing ESRD. EPO
Dose, I-Hct, A-Hct, and the number of dialysis sessions
were derived from HCFA’s Quarterly EPO Billing File.
The PMMIS Enrollment File was the source for informa-
tion regarding age, race, and sex. The underlying disease
causing ESRD was obtained from the PMMIS Medical
Evidence File and provider status was extracted from
ESRD Facility Survey files.
Patient selection
Using seven years of outpatient claims data that com-
prised all Medicare-entitled ESRD hemodialysis patients in
the U.S. for the years 1990-1996, seven cohorts incident to
rHuEPO therapy reimbursed by Medicare during the first
quarters of the years 1990 to 1996 were identified. Based on
previous research regarding exposure to rHuEPO [1, 6],
each cohort was followed for a minimum of three months
and a maximum of four months starting in the first quarter
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of each calendar year. Exposure to rHuEPO for 12 weeks
or more was deemed necessary to ensure a stable A-Hct.
The variability in follow-up periods results from the report-
ing of a total rHuEPO dose and a single A-Hct on a
calendar monthly basis, despite the fact that a person may
have initiated Medicare reimbursed treatment at any point
during the month.
All study patients met the following clinical and billing-
related criteria: initial reimbursement by Medicare for
rHuEPO therapy occurring during the first calendar quar-
ters of 1990 through 1996; be at least 18 years old; receive
rHuEPO on an outpatient in-center basis; be treated with
hemodialysis; not receive a kidney transplant during the
observation period; have both an I-Hct and A-Hct less than
0.60, but not below 0.10; and have at least one outpatient
bill for rHuEPO services during the third or fourth calen-
dar month after Medicare initiated payment for rHuEPO
services. A total of 64,957 patients met these study popu-
lation selection criteria between 1990 and 1996.
Since hospitalization could interrupt dosing of rHuEPO,
all analyses were conducted with and without the 1,216
patients who were hospitalized at some point during the
study period. There was no statistically significant differ-
ence after including a dummy variable for hospitalization in
the response to rHuEPO based on I-Hct. Using a number
of interaction terms between hospitalization and patient
characteristics, only race and hospitalization were signifi-
cant between groups (P 5 0.03). Therefore, hospitalization
was not used as an exclusion criteria. Finally, persons
receiving transfusions of one or more blood units were not
excluded from the study population. Blood units adminis-
tered are identifiable in claims data only if the provider
charges for the blood units, a practice that varies across
states. Furthermore, Eschbach reported that receipt of
blood was not used as an exclusion criteria in earlier clinical
trials [1].
In summary, seven unique patient cohorts, one for the
first quarter of each calendar year, were identified. These
cohorts were disaggregated into three groups based on
their I-Hct: less than 0.25, severely anemic; between 0.25
and 0.29, moderately anemic; and equal to or greater than
0.30, mildly anemic. Each patient in the study population
was observed for approximately 97 days [standard deviation
(SD), 21 days], during which time the patients received
approximately 34 rHuEPO administrations (SD, 11 admin-
istrations).
Statistical methods
Differences in patient demographics, clinical character-
istics and facility characteristics were tested using Pearson’s
chi-square statistic. Differences in the change in Hct across
the seven years and between patient and provider charac-
teristics were tested using an ANOVA model. Individual
comparisons between years were tested using the Tukey
method of multiple comparisons. Finally, a multivariate
regression was modeled using the A-Hct as the dependent
variable predicted by the I-Hct, rHuEPO dose per day and
various patient and provider characteristics. We did not
employ multivariate regression techniques for this study
since: (1) individual rHuEPO therapy session data are not
available; and (2) critical variables required to explain the
variability in A-Hct are not available from the claims data
(such as, iron supplementation and patient weight). All
differences with a P value less than or equal to 0.05 were
considered to be significant.
RESULTS
The demographic and clinical characteristics of the
hemodialysis study population are presented in Table 1.
The ESRD population incident to Medicare-reimbursed
rHuEPO was largest in 1990 as a result of the large number
of anemic patients who initiated treatment soon after the
introduction of rHuEPO in June 1989. The overall popu-
lation using rHuEPO increased during the following six
calendar years (1991 to 1996), reflecting both the wider use
of rHuEPO and the increasing size of the ESRD popula-
tion in the U.S. (P , 0.05). Except for 1990, there were
more men incident to rHuEPO therapy in the Medicare
program in each subsequent study year compared to
women. The age distribution of the study population
remained relatively constant from 1991 to 1996, with the
majority of patients over the age of 65 years. More than half
of the racial composition of the study population was
classified as white, one-third or more as African-American
and the remainder was classified as other (primarily Asian
or Native American). The proportion of African-Ameri-
cans initiating rHuEPO therapy reimbursed by Medicare
decreased during the seven year period from 39.1% in 1990
to 31.5% in 1996. The proportion of all patients with
diabetes as an underlying cause of ESRD increased notably
from 30% of the population in 1990 to 42% in 1996 (P ,
0.05). Hypertension as an underlying cause of ESRD
decreased across the study period; similarly, the proportion
of patients with glomerulonephritis and other interstitial
kidney diseases decreased from 16% to 12% (P , 0.05).
Almost two-thirds of the study population received both
hemodialysis and rHuEPO services in for-profit facilities,
while the remaining one-third were treated in non-profit
facilities.
The proportion of patients by I-Hct category incident to
rHuEPO therapy reimbursed by Medicare shifted dramat-
ically over the course of the study period (Table 1 and Fig.
1). In 1990, 33.2% of the study population were severely
anemic, 42.5% were moderately anemic and one-fourth
were mildly anemic. Over the seven-year study period, the
proportion of patients incident to rHuEPO reimbursed by
Medicare with severe anemia decreased notably; by 1996,
only 10.2% had severe anemia, while 54.9% had only mild
anemia (P , 0.05).
The mean I-Hct for the study population, disaggregated
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by severe, moderate and mild anemia, across the study
period is presented in Figure 2A. RHuEPO dosing in-
creased dramatically across the seven-year study period and
was associated with a small increase in A-Hct in each
subsequent year (Fig. 2 B, C and D). For example, for each
of the three anemia cohorts, the percentage increase in
mean rHuEPO dose per day between 1990 and 1996 was
139% for the severely anemic cohort, 122% for the mod-
erately anemic cohort, and 107% for the mildly anemic
cohort, corresponding to a 10%, 8% and 7% increase in
A-Hct for each anemia cohort, respectively (P , 0.05). In
terms of a realized improvement in the A-Hct level, the
increase in dose resulted in a 0.028, 0.023 and 0.02 increase
in A-Hct across the seven-year study period in each cohort,
respectively. For severely anemic patients initiating
rHuEPO therapy, the average rHuEPO dose increased
from 1,750 units to 2,285 units per day, while the average
A-Hct increased from 0.27 to 0.30 from 1990 to 1996 (P ,
0.05).
RHuEPO dose and both I-Hct and A-Hct across the
study period were analyzed based on age, gender, and race
(Fig. 3 A and B, 3 C and D, and 3 E and F, respectively).
While the rHuEPO dose administered was not statistically
different based on race, African-Americans had both a
lower I-Hct and A-Hct than whites in all study years (P ,
0.05). The increase in A-Hct in Figure 3A parallels the
increase in the I-Hct for the population between 1990 and
1996, suggesting the improvement in A-Hct may be influ-
enced by the fact that the study population is increasingly
less anemic. Persons under age 65 received similar
rHuEPO doses compared to persons over age 65 and both
age cohorts had similar I-Hct values across the study
period. Unexpectedly, the elderly population had a 0.01
higher A-Hct in each study year. Males and females
received similar doses of rHuEPO therapy across the study
period. Similarly, the improvement in A-Hct by gender
during this time appears to parallel the increase in I-Hct
among each group. Diabetes as an underlying cause of
ESRD did not appear to influence rHuEPO dosing or I-Hct
or A-Hct values (data not shown). Finally, there was a
difference in dosing of rHuEPO in 1990, 1991 and 1992
based on provider status, that is, for-profit facilities initially
provided lower rHuEPO doses compared to non-profit
facilities (data not shown, P , 0.05). After 1992, however,
Table 1. Demographic and clinical characteristics of ESRD patients incident to rHuEPO therapy reimbursed by Medicare during the first quarter
of 1990–1996
Covariate 1990 1991 1992 1993 1994 1995 1996
N 11,722 7,346 7,938 8,780 9,077 9,781 10,339
Percentage
Gender
Male 49.3 52.0 52.1 52.4 52.8 52.6 53.0
Female 50.7 48.1 48.0 47.6 47.2 47.4 47.0
Age years
18–34 9.0 7.8 6.6 7.2 6.9 6.2 5.1
35–64 45.7 41.0 40.1 39.8 39.1 39.0 39.4
651 45.3 51.2 53.3 53.0 54.0 54.8 55.6
Missing 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Race
White 53.1 55.9 58.7 59.6 59.6 60.4 60.7
Black 39.1 36.2 33.9 33.7 34.0 32.1 31.5
Other 6.1 6.3 5.9 5.7 5.9 6.9 7.2
Missing 1.7 1.7 1.5 1.0 0.5 0.6 0.6
Primary cause of ESRD
Diabetes 30.0 33.9 36.5 37.1 37.0 39.0 42.3
Hypertension 29.4 30.9 31.2 30.0 30.6 28.1 25.2
Glomerulonephritisa 18.8 16.1 15.3 13.8 14.4 13.0 13.8
Otherb 10.6 9.9 9.3 9.5 8.6 7.5 8.2
Unknown/unspecified 4.4 4.8 4.5 4.8 4.8 4.8 7.4
Missing 6.8 4.4 3.2 4.8 4.7 7.7 3.2
Provider status
Profit 62.8 60.1 62.0 61.6 62.5 63.4 64.9
Non-profit 32.8 35.2 33.5 33.5 32.7 32.7 30.8
Government 4.4 4.6 4.3 4.6 4.5 3.7 3.7
Unknown/other 0.1 0.1 0.2 0.4 0.3 0.3 0.6
Initial Hct
,0.25 33.2 26.4 21.6 18.3 14.9 12.7 10.2
0.25–0.29 42.5 44.9 44.7 41.8 40.1 36.9 34.9
0.301 24.3 28.7 33.6 39.9 45.0 50.4 54.9
a Includes other interstitial kidney diseases such as kidney infections and polycystic disease
b Other includes systemic lupus erythematosus, multiple myeloma, congenital, metabolic disorders and sickle cell anemia
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there was no significant difference in rHuEPO dosing
based on facility profit status.
The response to rHuEPO (the difference between the
I-Hct in month one and the A-Hct at least 12 weeks later)
is presented by year in Table 2. The aggregate change in
Hct for the study years 1991 through 1996 is similar. For
illustrative purposes, response to rHuEPO therapy was
categorized by a Hct change as follows: .0.02 points;
between 0.02 and 20.02; and , 20.02 points. The propor-
tion of patients that comprised each of the three response
categories was similar for every study year, suggesting that
the response to rHuEPO, measured by improvement in Hct
levels, did not change markedly over the seven year period.
The mean Hct change in 1990 was significantly larger than
in subsequent years (mean change of 0.023 Hct points vs. a
high of 0.021 to a low of 0.018, depending on the year; P ,
0.0001), reflecting the large cohort of severely anemic
patients present in 1990. Among the potential confounders
that may be associated with the level of response to
rHuEPO [12, 13], African-Americans, the elderly, non-
diabetics and persons receiving dialysis in a non-profit
facility had a significantly larger change in Hct compared to
their counterparts (P , 0.0001). Unadjusted, the most
significant predictor of rHuEPO response, however, was
I-Hct: the lower the I-Hct, the larger the change in Hct.
Results of the multivariate analysis concur with the
findings reported in Table 2. In addition, the multivariate
model indicates that the I-Hct is the most important
predictor of both A-Hct and change in Hct after a mini-
mum 12-week rHuEPO therapy, adjusting for patient de-
mographics, underlying cause of ESRD, type of dialysis
facility, year in which rHuEPO therapy was initiated, and
rHuEPO dose per day-at-risk. Because of the caveats
associated with the regression model discussed earlier in
the statistical methods section, these results are not pre-
sented separately.
Notably, for persons with an I-Hct greater than 0.30,
there was a failure to achieve an increase in Hct levels,
shown by a negative change of 0.009 Hct points between the
I-Hct and A-Hct. For simplicity, a failure to achieve an
increase in patient hematocrit levels is subsequently re-
ferred to in the text and attached tables as a ‘negative
change.’ To further investigate this phenomena, we com-
bined all three anemia cohorts and disaggregated them into
two groups: those who had a positive A-Hct change and
those who had a negative A-Hct change (Table 3). Overall,
we observed that 68.7% of all the patients had an improved
A-Hct with a mean increase of 10.0449 Hct points and
31.7% of the patients had an A-Hct with a mean decrease
of 20.0337 Hct points lower than their I-Hct. We subdi-
vided these groups by age, gender, race, and primary cause
of renal failure and found a response similar to the overall
group (data not shown). We also subdivided these groups
by the three I-Hct categories and found severely anemic
patients with a 91.9% positive response (with a mean
increase of 10.0684 Hct points) and 8.1% with a negative
response (with a mean decrease of 20.022 Hct points).
Moderately anemic patients had a 78.7% positive response
(10.0433 Hct points) and 21.3% with a negative response
(with a mean decrease of 20.0269 Hct points). Mildly
anemic patients had a 47.0% positive response (with a
mean increase of 10.0229 Hct points) and 53.0% with a
negative response (with a mean decrease of 20.0374 Hct
points). We also subdivided these groups by age, gender,
race, and primary cause of renal failure and found a
response similar to the overall group as stated above.
DISCUSSION
In interpreting the findings of this research, several areas
warrant discussion: the transition from controlled trials to
broader clinical use (and the associated policy and financial
Fig. 1. Proportion of the study population
disaggregated by initial hematocrit incident to
recombinant human erythropoietin (rHuEPO)
therapy reimbursed by Medicare. Symbols are:
(f) ,0.25; (M) 0.25 to 0.29; (u) .0.30.
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incentives); resistance to rHuEPO therapy; inadequate
supplementation of iron among iron deficient patients; and
the impact of reimbursement policies and financial incen-
tives. Finally, the role of adequacy of dialysis and mem-
brane clearance in relation to rHuEPO therapy are cur-
rently undetermined and warrant further research.
Transition from clinical trials to the broader clinical
arena
Based on clinical trial results, rHuEPO was determined
to be highly effective in ameliorating anemia among per-
sons with ESRD receiving hemodialysis therapy [1, 2].
Unlike the dramatic results observed in the clinical trials
where the mean rHuEPO dose was 225 U/kg/week, a Phase
IV study of the effectiveness of rHuEPO used in broader
clinical practice concluded that “patients do not seem to be
realizing the full potential beneficial effects of this remark-
able agent” presumably because low doses of rHuEPO,
with a mean rHuEPO dose of 100 U/kg/week were being
used, resulting in a low mean A-Hct level [6]. In contrast to
our study, Nissenson et al did not disaggregate their
analysis, findings and conclusions by patients’ I-Hct. The
authors were told by participating centers that HCFA’s
initial reimbursement regulations were the primary reason
why physicians administered rHuEPO in doses lower than
those used in the clinical trials (for example, dosing at 100
U/kg/week vs. 150 to 300 U/kg/week used in the Phases I
and II clinical trials was required to achieve a Hct .0.30).
Others argued that it was a new drug, and therefore,
physicians were initially very conservative in its use. The
dosing regimen in Phase IV, based on an average dose of
100 U/kg/week for incident rHuEPO patients, resulted in a
mean A-Hct level of 0.31, lower than that achieved in the
earlier clinical trials. Furthermore, only 58% of all patients
achieved a Hct level greater than 0.30. Another variation in
clinical practice reported by the Prospective Payment As-
sessment Commission was that rHuEPO dosages were not
necessarily increased for patients with lower Hct values
during the period from 1989 to 1990 [14]. Previously, Sisk,
Gianfrancesco and Coster showed that fewer than 45% of
patients who had been treated for six months or more prior
to August 1990 had ever attained the target Hct of 0.30 to
0.33 set by HCFA [9].
The Medicare payment policy for rHuEPO treatment for
dialysis patients changed in January 1991 from a relatively
fixed payment per treatment based on an allowed charge of
$40 per dose under 10,000 units injected to variable pay-
ment based on an allowed charge of $11 for each 1,000
units injected. The change in insurance payment policy in
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Fig. 2. Initial (A), achieved (B) and D hematocrit (C; achieved hemato-
crit 2 initial hematocrit) and the rHuEPO (D) dosing patterns among the
study population disaggregated by initial hematocrit during the years
1990 to 1996. Symbols in panels A, B, and D are: () ,0.25; (f) 0.25 to 0.29;
(F) .0.30. Symbols in panel C are: (f) ,0.25; (F) 0.25 to 0.29; () .0.30.
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combination with increasing experience with use of
rHuEPO appeared to influence dosing practices of dialysis
providers, particularly at for-profit dialysis centers [15].
There was a trend toward increasing average charges for
rHuEPO per treatment during the observation period after
the change in payment policy [16].
Fig. 3. Hematocrit values and rHuEPO dosing
based on selected patient characteristics for the
years 1990 to 1996. (A) Hematocrit by age
(,65 and $65). (B) EPO dose by age (. 65
and #65). (C) Hematocrit by gender. (D) EPO
dose by gender. (E) Hematocrit by race. (F)
EPO dose by race. Symbols in panels A and B
are: (M) A-Hct $ 65; (V) A-Hct , 65; (f)
I-Hct $ 65; (v) I-Hct , 65; () EPO dose
,65; () EPO dose $ 65. Symbols in panels C
and D are: (M) A-Hct female; (V) A-Hct male;
(f) I-Hct female; (v) I-Hct male; () EPO
dose male; () EPO dose female. Symbols in
panels E and F are: (M) A-Hct black; (V) A-
Hct white; (f) I-Hct black; (v) I-Hct white;
() EPO dose white; () EPO dose black.
Abbreviations are: I-HCT, initial hematocrit;
A-HCT, achieved hematocrit.
Cotter et al: Secular trends in erythropoietin therapy 2135
Following the change in the payment method from a
fixed amount to one based on the dose administered,
dosing increased markedly. However, Hct levels still re-
mained below the optimal level of 0.30 [7]. Several expla-
nations are plausible, including the possibility that the
clinical symptoms of anemia in this range may not be fully
appreciated by physicians for this patient population; the
principles of rHuEPO therapy may not be adequately
followed; there may be concern about potential “side
effects” of administering rHuEPO; there may be a bias that
moderate anemia is acceptable for dialysis patients, al-
though not for “healthy” subjects; and the relative lack of
published physiological studies designed to determine the
optimal target Hct [17]. Other explanations include inade-
quate iron supplementation (discussed in the next section),
inadequate nutrition, and less than complete blood recov-
ery during the dialysis procedure. Finally, HCFA’s reim-
bursement policy itself, that is, an upper limit of 0.36 on the
hematocrit that would normally be reimbursed without
accompanying documentation provided by a physician, may
also have contributed to the suboptimal response to
rHuEPO seen in this article.
Since the end of our study, two new policy initiatives
regarding Medicare’s coverage of erythropoietin have been
enacted by HCFA. The first policy, dated May 1997,
instructed that no payment was to be made during a month
if the 90-day average hematocrit exceeded 0.365. This was
subsequently rescinded in March 1998, re-establishing the
policy that was in place during the majority of this study.
The motivation behind these policy initiatives is unclear as
are the potential effects they have on rHuEPO dosing and
patient hematocrit. The unexpected reversal of the original
“three months rolling average” policy indicates the contin-
ued involvement of Congress and HCFA in regulating EPO
use and pricing.
We speculate that the vast majority of patients in the
study with initial mild anemia may have received rHuEPO
therapy prior to this service being reimbursed by Medicare
and are therefore being maintained in this hematocrit
range. This occurrence is due to the HCFA required
three-month waiting period after the onset of ESRD that
must lapse before Medicare pays for this service. Based on
the Medicare secondary payer (MSP) indicator found in
the enrollment records, an average of 1.0% of severely
anemic, 1.4% of moderately anemic, and 2.4% of mildly
anemic patients in the study may have received EPO
therapy prior to reimbursement by Medicare. This occur-
rence is due to MSP rules that require other payers to
reimburse for rHuEPO therapy if the patient is covered by
an employer group health plan. Since the Medicare data-
base used in this study does not contain records for other
carriers, this MSP rule offers no access to their prior
rHuEPO history.
A portion of the mildly anemic cohort may have received
rHuEPO therapy at a Hct level slightly below 0.30, and that
by the end of the first month of rHuEPO treatment their
Hct rose above 0.30 to a value that we observed and
reported as their I-Hct. Also, some of the patients con-
tained in this cohort may have initiated rHuEPO therapy at
Hct levels higher than 0.30 if there was medical documen-
tation showing the need for rHuEPO. For example, HCFA
also allows payment for these patients if they have angina,
pulmonary distress, or hypotension and may require
rHuEPO to prevent adverse symptoms even if they have
higher Hct or hemoglobin levels. For the mildly anemic
cohort, the change in Hct over a minimum observed
12-week study period was slightly negative. This negative
change could be associated with the difficulty in maintain-
ing a stable Hct above 0.30 and below the target Hct levels
imposed by HCFA.
Resistance to rHuEPO therapy
In addition to the change in reimbursement policy, the
more aggressive use of rHuEPO among an increasing
number of rHuEPO resistant patients has been postulated
Table 2. Response to rHuEPO therapy by year and by selected patient
and provider characteristics
N
% of Patients
by change in
hematocrit
points Mean
change
in Hct
P
valuea,20.02
20.02 to
0.02 .0.02
Total 64,957 17.8 35.6 46.6 0.0195
Year
1990 11,715 16.3 33.4 50.3 0.0234 0.0001b
1991 7,346 16.7 36.0 47.3 0.0206
1992 7,934 18.3 36.9 44.8 0.0179
1993 8,772 18.5 36.4 45.1 0.0182
1994 9,074 18.4 37.5 44.2 0.0181
1995 9,780 18.2 35.4 46.3 0.0198
1996 10,336 18.3 34.9 46.8 0.0201
Initial Hct
,0.25 12,786 3.07 17.3 79.6 0.0611 0.0001
0.25–0.29 26,363 10.29 33.0 56.8 0.0283
0.301 25,808 32.72 47.5 19.8 20.0090
Facility
For-profit 40,676 17.8 36.6 45.6 0.0192 0.0001
Non-profit 21,362 17.8 34.2 48.1 0.0209
Cause of ESRD
Diabetic 23,694 18.1 36.1 45.8 0.0189 0.0001
Non-diabetic 41,263 17.6 35.4 47.0 0.0205
Race
White 37,804 17.8 36.3 45.9 0.0194 0.0001
Black 22,367 17.7 34.4 47.9 0.0210
Age years
,65 30,994 19.2 37.7 43.2 0.0168 0.0001
$65 33,958 16.5 33.8 49.7 0.0227
Gender
Male 33,732 17.3 35.9 46.8 0.0204 0.0171
Female 31,225 18.3 35.4 46.3 0.0194
a Difference in means between each characteristic level
b Mean change in hematocrit in 1990 is significantly greater than the
mean of each subsequent year
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as an important reason to explain the significantly increas-
ing dose over the past seven years, without a concomitantly
large increase in A-Hct. For example, pathologic conditions
of the bone marrow, such as myelofibrosis or hypoplasia, or
inadequate stores of required nutrients such as iron, folic
acid, and vitamin B12 can dampen the Hct response,
producing “resistance” to rHuEPO [18–21]. In the Phase
III trial, 17% of all patients required greater than 150 U/kg
in order to maintain a stable Hct. Nonresponders to
rHuEPO, who comprised less than 2% of the Phase III
study population, had the following causes of anemia:
myelofibrosis, osteitis fibrosa, osteomyelitis and acute or
chronic blood loss [1].
To investigate whether there was a fundamental shift
toward greater resistance over time, we compared the
change in Hct over a minimum of 12 weeks as a proxy for
characterizing the dose response of these patients from
1990 through 1996. In profiling the difference between
their I-Hct and A-Hct, we did not find a shift in the
distribution of patients based on Hct response to rHuEPO
therapy across the study period, as shown in Table 2. The
proportion of nonresponders as indicated by the percent-
age of patients with less than a 2% point change in
hematocrit was stable across the study period comprising
approximately 18% of all patients in each year.
Role of supplemental iron
The most common cause of decreased responsiveness to
rHuEPO among patients with chronic renal failure is
insufficient iron stores [22, 23]. Untreated iron deficiency
reduces the effectiveness of rHuEPO and adds unnecessary
cost to the treatment as well as delays to patient rehabili-
tation [24]. The necessity of administering oral and/or
intravenous iron concomitantly with rHuEPO has been well
established and widely disseminated [25, 26], including by
the Anemia Cooperative Project [27], whose goal is to
advance the treatment of anemia among dialysis patients in
the U.S. While oral iron supplementation was available
throughout the study period, intravenous supplementation
was only available during the years 1991 to 1994, although
some providers may have stockpiled it and used their
supply during the time when intravenous iron was unavail-
able. Such supplementation is often less than optimal in
clinical practice [16] and oral iron supplementation is often
inadequate to replete iron stores [28]. Such iron deficiency
may result in a less than expected effect of rHuEPO on Hct.
This study did not include information on iron supplemen-
tation among persons receiving rHuEPO, although it is
anticipated that iron deficiency existed among members of
the study population.
In another example, in a USRDS special study, the
Dialysis Morbidity and Mortality Study (DMMS wave 1),
iron deficiency among the dialysis population included in
this study was evaluated [29]. The DMMS found that more
than 50% of the 2,613 dialysis patients examined in 1993
had transferrin saturation levels of ,20%, 36% had serum
ferritin levels of ,100 ng/ml, and 56% had serum ferritin
levels of ,200 ng/ml. Furthermore, only 11.2% of these
patients had received i.v. iron, while 25% had received
neither i.v. nor oral iron. HCFA’s 1997 ESRD Core
Indicators Project also reported data on the treatment of
iron deficiency among the ESRD population [30]. The
Core Project found that the national average percent
transferrin saturation for patients in their sample (October
to December 1996 survey period) was 27.4% and ranged
from 24.7% to 29.4%. Nationally 63% of the patients
(ranging from 49% to 75%) had transferrin saturation
values $ 20%. They also reported that the national average
ferritin level was 377 ng/ml and ranged from 320 to 426
Table 3. Overall response to rHuEPO therapy based on the change
between the initial hematocrit and the achieved hematocrit by
selected patient characteristics
Subgroups
Response
(1 positive,
2 negative)
Mean
subgroup
change
in Hct
points
P
value
Number
of
patients
N
Percent
of
subgroup
%
All (1) 0.0449 0.0001 44,624 68.7%
All (2) 20.0337 20,333 31.3%
Initial Hct.
,0.25 (1) 0.0684 0.0001 11,754 91.9%
,0.25 (2) 20.0220 1,032 8.1%
0.25–0.29 (1) 0.0433 20,742 78.7%
0.25–0.29 (2) 20.0269 5,621 21.3%
0.301 (1) 0.0229 12,128 47.0%
0.301 (2) 20.0374 13,680 53.0%
Age years
651 (1) 0.0459 0.0001 24,059 70.8%
651 (2) 20.0335 9,899 29.2%
,65 (1) 0.0426 20,561 66.3%
,65 (2) 20.0339 10,433 33.7%
Race
White (1) 0.0435 0.0001 25,853 68.4%
White (2) 20.0328 11,951 31.6%
Black (1) 0.0460 15,491 69.3%
Black (2) 20.0352 6,876 30.7%
Other (1) 0.0435 2,801 68.3%
Other (2) 20.0348 1,301 31.7%
Gender
Male (1) 0.0443 0.0001 23,303 69.1%
Male (2) 20.0331 10,429 30.9%
Female (1) 0.0444 21,321 68.3%
Female (2) 20.0344 9,904 31.7%
Cause of ESRD
Diabetes (1) 0.0434 0.0322 16,163 68.2%
Diabetes (2) 20.0337 7,531 31.8%
Hypertension (1) 0.0455 13,250 69.9%
Hypertension (2) 20.0337 5,699 30.1%
Glomerulonephritisa (1) 0.0447 6,776 69.1%
Glomerulonephritisa (2) 20.0343 3,026 30.9%
Otherb (1) 0.0454 3,974 67.3%
Otherb (2) 20.0328 1,929 32.7%
a Includes other interstitial kidney diseases such as kidney infections
and polycystic disease
b Other includes systemic lupus erythematosus, multiple myeloma,
congenital, metabolic disorders and sickle cell anemia
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ng/ml. Nationally 73% of the patients (ranging from 60% to
80%) had ferritin levels $ 100 ng/ml.
The results of this study lend credence to the salient
clinical need to ascertain the appropriate target hematocrit
levels for patients based on their medical condition. The
initial clinical trials and physiologic and quality of life
studies of anemic dialysis patients treated in the U.S. and in
Europe had target hematocrit levels .0.36. Virtually all of
these studies showed that the increased Hct levels were
concomitant with improvements in various physiologic
measures [31–37]. However, since the FDA initially ap-
proved a target Hct level of 0.30 to 0.33 in June 1989 (and
later widened it to 0.36 in June 1994) and HCFA imposed
a policy under which it limited reimbursement to hemato-
crit values under 0.36, there have been no new studies in
the U.S. to examine the potential beneficial effects of an
achieved hematocrit value .0.36. In their analysis of this
issue, based on a medical literature review, the Anemia
Work Group concluded that hematocrit values ,0.33 were
associated with increased morbidity and mortality com-
pared to those .0.36 [38]. A widely noted exception to this
conclusion is the preliminary results of a study that exam-
ined 1,200 hemodialysis patients with heart disease that was
discontinued when patients with a target hematocrit in the
normal range (0.39 to 0.45) began to experience a greater
incidence of non-fatal myocardial infarctions or death than
did the control group with a target hematocrit in the range
of 0.27 to 0.33 [38]. No conclusions, however, can be drawn
from this study regarding ESRD patients with anemia who
do not have heart disease. This study combined with
additional concerns regarding other possible side effects of
rHuEPO therapy, led the Anemia Work Group to recom-
mend that Hct levels be maintained between 0.33 and 0.36,
pending new studies [39].
Future studies to clarify the relationship between
rHuEPO dose and Hct and patient outcomes are clearly
warranted, including the empirical determination of the
purported non-linear dose-response relationship. In addi-
tion, the cost implications of achieving higher target Hct
levels, especially among mildly anemic patients, need to be
examined. Finally, quality-of-life studies have been pub-
lished based on severely anemic patients included in the
clinical trial patient population [39] and elsewhere on the
moderately anemic ESRD population [40]. Studies are
therefore needed to determine quality-of-life improve-
ments as well as the cost-effectiveness resulting from
rHuEPO therapy for patients who are maintained at a
mildly anemic level, who represent the majority of ESRD
hemodialysis patients currently receiving rHuEPO therapy.
In conclusion, our results concur with USRDS findings
that after an almost doubling of the dose of rHuEPO per
patient between 1990 and 1996 (from 2,700 to 4,900
units/administration), the mean Hct for the ESRD medi-
care hemodialysis patient population increased by only 3
percentage points during the same period (from 0.0285 to
0.314) [5]. Overall, our research findings also suggest that
substantial increases in rHuEPO dose provided to anemic
patients over the seven year study have resulted in only
modest increases in Hct.
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